GLIOBLASTOMA FOUNDATION INC (EIN 812849764) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2016

Legal Domicile

Principal Officer

MADAN KWATRA

Phone

9193091489

Tax Period

2024-01-01 to 2024-12-31

GLIOBLASTOMA FOUNDATION INC, founded in 2016, is a community nonprofit in the Medical Research sector that reported $2.1M in total revenue in fiscal year 2024. Revenue surged 21% from the prior year, signaling strong growth momentum. Expenses of $1.8M left a modest 11% surplus.

Mission

TO IMPROVE TREATMENT OPTIONS FOR GLIOBLASTOMA PATIENTS BY FUNDING INNOVATIVE RESEARCH, EXPANDING ACCESS TO GENOMIC TESTING, SUPPORTING PATIENTS AND FAMILIES, AND RAISING NATIONAL AWARENESS OF THIS AGGRESSIVE BRAIN CANCER.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $1,964,537

Program Service Revenue $0

Investment Income $2,803

Other Revenue $87,878

TOTAL REVENUE $2,055,218

Expense Breakdown

Grants Paid $97,474

Salaries & Benefits $696,475

Fundraising Expenses $13,930

Program Expenses $1,581,752

Other Expenses $1,039,715

TOTAL EXPENSES $1,833,664

Year-over-Year Comparison

	2024	2023	Change
Revenue	$2,055,218	$1,699,784	+0.2%
Expenses	$1,833,664	$1,411,492	+0.3%
Net Income	$221,554	$288,292	-0.2%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

150

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$343,048

Total Directors

$343,048

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
NEELAM KWATRA	PRESIDENT	20.00	Officer Director	$0	$0	$0
MADAN KWATRA	TREASURER/SECRETARY	4.00	Officer Director	$0	$0	$0
GITA KWATRA	CEO	40.00	Officer Director	$291,500	$51,548	$343,048
CAMERON WEST	BOARD MEMBER	1.00	Director	$0	$0	$0
BRIAN AUSTIN	BOARD MEMBER	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$2,055,218	$1,833,664	$3,662,658	$221,554
2023	$1,699,784	$1,411,492	$2,482,026	$288,292
2022	$1,471,550	$853,578	$1,781,399	$617,972
2021	$1,253,574	$703,351	$1,523,936	$550,223
2020	$958,672	$323,928	$1,140,681	$634,744
2019	$448,677	$296,591	$455,940	$152,086

GLIOBLASTOMA FOUNDATION INC